Cesar L Alvarez
CIK 1220297 · last filed 2026-03-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 901
MIAMI, FL 33133
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | Director | 782,909 | $6.36 | $4.98M | $0 | 15 | 2026-03-16 |
| WSO.B | Director | 0 | $287.50 | $0 | -$5.46M | 8 | 2025-03-07 |
| MD | Director | 48,403 | $29.52 | $1.43M | -$7.13M | 19 | 2020-02-18 |
| PRECIGEN, INC. (XON) Delisted | Director | 125,368 | — | — | $0 | 18 | 2019-03-26 |
| JOE | Director | 4,700 | $69.72 | $327.7K | $89.8K | 5 | 2018-03-19 |
| PDX | Director | 10,000 | $20.24 | $202.4K | $0 | 4 | 2008-05-23 |
| NEW RIVER PHARMACEUTICALS INC (NRPH) Delisted | Director | — | — | — | $0 | 1 | 2007-01-31 |
Recent Filings · Page 3 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-03 | WSO.B | Grant (A) | — | $0 | EDGAR |
| 2020-03-17 | PGEN | Grant (A) | +31,094 | $62.5K | EDGAR |
| 2020-03-10 | PGEN | Exer (M) | +24,703 | $0 | EDGAR |
| 2020-02-18 | MD | Grant (A) | +4,717 | $0 | EDGAR |
| 2019-06-05 | WSO.B | Grant (A) | — | $0 | EDGAR |
| 2019-03-26 | PRECIGEN, INC. (XON) Delisted | Exer (M) | +7,911 | $0 | EDGAR |
| 2019-03-12 | PRECIGEN, INC. (XON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-21 | PRECIGEN, INC. (XON) Delisted | Exer (M) | +2,968 | $9.4K | EDGAR |
| 2019-02-14 | MD | Grant (A) | +3,699 | $0 | EDGAR |
| 2018-05-08 | MD | Mixed | +4,090 | -$17 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.